Condition: Episodic Cluster Headache
Interventions: Drug: Fremanezumab – A; Drug: Fremanezumab – B; Drug: Placebo
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting – verified August 2017
Source: ClinicalTrials.gov Listing of Cluster Headache trials
This is a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the efficacy and safety of 2 dose regimens of TEV-48125 (Fremanezumab) versus placebo in adult patients for the prevention of ECH.
2016-10-25